Lung Cancer Liquid Biopsy Market Growth To $2.42 Billion By 2030: What’s Driving The Expansion?

Lung Cancer Liquid Biopsy Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Lung Cancer Liquid Biopsy Market Value Growth And Long-Term Outlook

The lung cancer liquid biopsy market has seen swift expansion in recent years. Its valuation is anticipated to climb from $1.12 billion in 2025 to $1.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.0%. This historical increase can be ascribed to factors such as rising lung cancer incidence rates, the drawbacks of tissue biopsy methods, advancements in molecular diagnostics, the availability of circulating biomarker technologies, and an uptick in oncology research endeavors.

The lung cancer liquid biopsy market size is anticipated to undergo significant expansion in the coming years. It is projected to achieve a valuation of $2.42 billion by 2030, progressing at a compound annual growth rate (CAGR) of 16.7%. This projected growth can be linked to several factors, including the surging demand for precision oncology solutions, the widening scope of liquid biopsy clinical applications, the increasing uptake of companion diagnostics, the escalating integration of AI-driven data analysis, and a heightened emphasis on early cancer screening programs. Prominent trends expected in this forecast period involve the rising adoption of non-invasive diagnostic techniques, the growing use of NGS-based liquid biopsy tests, an expanding need for early cancer detection, the development of personalized oncology diagnostics, and the improved integration of bioinformatics platforms.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=21197373&type=smp&name=Lung%20Cancer%20Liquid%20Biopsy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lung Cancer Liquid Biopsy Market Expansion Drivers: What’s Shaping Future Growth?

The rising occurrence of lung cancer is anticipated to boost the expansion of the lung cancer liquid biopsy market in the coming years. This condition involves the unchecked multiplication of atypical cells within the lungs, frequently stemming from smoking and environmental factors. The primary reason for the increase in lung cancer cases is ongoing tobacco consumption, as smoking introduces carcinogens to the lungs that stimulate irregular cell development. Lung cancer liquid biopsy offers assistance by identifying cancer-associated genetic mutations and tumor DNA through a blood sample, thereby facilitating early detection, selection of appropriate treatments, and tracking disease progression or therapeutic response. For instance, in January 2023, a report from the American Cancer Society (ACS), a U.S.-based nonprofit organization, projected that in 2023, approximately 238,340 individuals, comprising 117,550 men and 120,790 women, would receive a lung cancer diagnosis, and 127,070 people are predicted to succumb to the illness. Consequently, the increasing prevalence of lung cancer is stimulating the growth of the lung cancer liquid biopsy market.

Lung Cancer Liquid Biopsy Market Segmentation And Category Overview

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Lung Cancer Liquid Biopsy Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies in the lung cancer liquid biopsy market are prioritizing the development of technological advancements, such as blood-based lung cancer screening tests, to boost early detection capabilities, improve diagnostic accuracy, and enable non-invasive, real-time monitoring of tumor progression and treatment response. A blood-based lung cancer screening test offers a non-invasive method, analyzing biomarkers in the bloodstream to identify the presence of lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology company, introduced FirstLook Lung, a blood-based liquid biopsy test created to assist in early lung cancer detection. This test utilizes fragmentomics to detect early lung cancer with high sensitivity and a 99.8% negative predictive value, making it a convenient and accessible initial step for at-risk individuals. Its objective is to enhance early detection, increase screening rates, and help direct further imaging resources to those most likely to benefit.

Lung Cancer Liquid Biopsy Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

View The Full Lung Cancer Liquid Biopsy Market Report:

https://thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lung Cancer Liquid Biopsy Market Regional Split: Which Areas Are Fueling Growth?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model